Table 2.
Accuracy of ElastPQ in Total Group.
| Stage | AUROC | Cutoff (kPa) | Sensitivity (%) | Specificity (%) | PPV (%) | NPV (%) | Accuracy (%) |
|---|---|---|---|---|---|---|---|
| All patients | |||||||
| Any fibrosis | 0.907 | 5.37 | 77.3 | 100 | 100 | 66.7 | 84.4 |
| Significant fibrosis | 0.959 | 5.96 | 100 | 86.4 | 76.9 | 100 | 90.6 |
| Advanced fibrosis | 0.926 | 8.42 | 80 | 92.6 | 66.7 | 96.2 | 90.6 |
| CVH | |||||||
| Any fibrosis | 0.955 | 5.37 | 90.9 | 100 | 100 | 80 | 93.3 |
| Significant fibrosis | 0.861 | 5.96 | 100 | 75 | 50 | 100 | 80 |
| Advanced fibrosis | 0.643 | 5.96 | 100 | 64.3 | 16.7 | 100 | 66.7 |
| CVH with ESRD | |||||||
| Significant fibrosis | 0.667 | 5.90 | 100 | 50 | 40 | 100 | 62.5 |
| Advanced fibrosis | 0.429 | 5.90 | 100 | 42.9 | 20 | 100 | 50 |
| CVH without ESRD | |||||||
| Any fibrosis | 0.833 | 5.57 | 66.7 | 100 | 100 | 80 | 85.7 |
| Significant fibrosis | 1.000 | 6.78 | 100 | 100 | 100 | 100 | 100 |
| NAFLD | |||||||
| Any fibrosis | 0.902 | 5.02 | 81.8 | 100 | 100 | 75 | 88.2 |
| Significant fibrosis | 1.000 | 5.87 | 100 | 100 | 100 | 100 | 100 |
| Advanced fibrosis | 0.981 | 8.04 | 100 | 92.3 | 80 | 100 | 94.1 |
| NAFLD with inactive HBsAg carrier state | |||||||
| Any fibrosis | 1.000 | 5.79 | 100 | 100 | 100 | 100 | 100 |
| Significant fibrosis | 1.000 | 5.79 | 100 | 100 | 100 | 100 | 100 |
| Advanced fibrosis | 1.000 | 12.57 | 100 | 100 | 100 | 100 | 100 |
| NAFLD without inactive HBsAg carrier state | |||||||
| Any fibrosis | 0.944 | 4.62 | 88.9 | 100 | 100 | 66.7 | 90.9 |
| Significant fibrosis | 1.000 | 6.04 | 100 | 100 | 100 | 100 | 100 |
| Advanced fibrosis | 0.958 | 8.04 | 100 | 87.5 | 75 | 100 | 90.9 |
CVH, chronic viral hepatitis; NAFLD, nonalcoholic fatty liver disease; ESRD, end-stage renal disease; ElastPQ, elastography point quantification; AUROC; area under the receiver operating characteristic; PPV; positive predictive value; NPV, negative predictive value.